agilon health, inc. (NYSE:AGL) Short Interest Update

agilon health, inc. (NYSE:AGL) saw a significant increase in short interest during the month of November. As of November 30th, there was short interest totalling 31,940,000 shares, an increase of 5.1% from the November 15th total of 30,390,000 shares. Currently, 10.5% of the shares of the company are short sold. Based on an average daily volume of 4,590,000 shares, the days-to-cover ratio is presently 7.0 days.

agilon health Price Performance

Shares of AGL stock traded up $0.02 during trading hours on Monday, hitting $2.26. 1,684,808 shares of the company’s stock were exchanged, compared to its average volume of 4,841,655. agilon health has a 52 week low of $1.50 and a 52 week high of $13.45. The stock has a market cap of $931.16 million, a price-to-earnings ratio of -2.38 and a beta of 0.51. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.29 and a quick ratio of 1.29. The stock’s 50-day moving average is $2.44 and its 200-day moving average is $4.38.

agilon health (NYSE:AGL) last released its earnings results on Thursday, November 7th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.19). The firm had revenue of $1.45 billion for the quarter, compared to the consensus estimate of $1.47 billion. agilon health had a negative return on equity of 47.84% and a negative net margin of 6.88%. During the same quarter in the previous year, the firm earned ($0.06) EPS. As a group, research analysts forecast that agilon health will post -0.52 EPS for the current year.

Insider Transactions at agilon health

In related news, Director Karen Mcloughlin purchased 25,000 shares of agilon health stock in a transaction dated Friday, December 13th. The stock was bought at an average cost of $2.20 per share, for a total transaction of $55,000.00. Following the transaction, the director now owns 73,166 shares in the company, valued at approximately $160,965.20. The trade was a 51.90 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director John William Wulf acquired 45,000 shares of the company’s stock in a transaction dated Thursday, December 5th. The shares were acquired at an average cost of $2.18 per share, with a total value of $98,100.00. Following the completion of the purchase, the director now owns 206,133 shares in the company, valued at approximately $449,369.94. This represents a 27.93 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 90,000 shares of company stock worth $198,100. Corporate insiders own 3.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of agilon health during the 3rd quarter worth approximately $28,000. CWM LLC boosted its holdings in shares of agilon health by 406.5% during the 2nd quarter. CWM LLC now owns 9,081 shares of the company’s stock worth $59,000 after buying an additional 7,288 shares during the period. Nisa Investment Advisors LLC bought a new stake in shares of agilon health during the second quarter worth approximately $60,000. Allspring Global Investments Holdings LLC increased its stake in shares of agilon health by 17,790.0% during the second quarter. Allspring Global Investments Holdings LLC now owns 10,734 shares of the company’s stock worth $70,000 after purchasing an additional 10,674 shares during the period. Finally, Pallas Capital Advisors LLC acquired a new position in agilon health in the 2nd quarter valued at $77,000.

Analysts Set New Price Targets

AGL has been the topic of several research analyst reports. Bank of America cut shares of agilon health from a “buy” rating to an “underperform” rating and set a $3.00 price target on the stock. in a research report on Wednesday, October 2nd. Stifel Nicolaus dropped their price target on agilon health from $7.00 to $2.00 and set a “hold” rating on the stock in a research report on Tuesday, November 12th. Evercore ISI lowered their price objective on agilon health from $7.00 to $4.00 and set an “in-line” rating for the company in a research note on Tuesday, October 8th. Citigroup reduced their price target on shares of agilon health from $2.50 to $1.75 and set a “sell” rating for the company in a report on Wednesday, November 13th. Finally, Barclays reduced their target price on shares of agilon health from $5.00 to $2.00 and set an “underweight” rating for the company in a research note on Monday, November 11th. Three research analysts have rated the stock with a sell rating, sixteen have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, agilon health presently has a consensus rating of “Hold” and an average target price of $4.28.

About agilon health

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.